Why ABM Is Uniquely Powerful in B2B Life Sciences - and Why Generic ABM Tools Often Fall Short

Account-Based Marketing was not invented for the life sciences. It was developed primarily in the B2B technology sector, refined by SaaS companies selling software to enterprise buyers, and packaged into platforms built to serve that context. The intent data that powers most ABM platforms was designed initially to surface the kinds of digital signatures that reveal that a company is researching a new CRM, evaluating a cybersecurity vendor, or exploring cloud infrastructure options.

Life science companies that approach ABM by simply adopting the SaaS playbook — the same tools, the same intent signals, the same targeting logic — are likely to find that the program underperforms. Not because ABM doesn't work in life sciences. Quite the opposite. ABM is arguably more naturally suited to B2B life science commercial environments than to any other B2B sector. But realizing the potential of ABM to drive pipeline in life science requires understanding what makes life science buyers different, and adapting the approach accordingly.

This post makes the case for why ABM and life sciences are a particularly strong fit, and also explains why the standard tools and playbooks built for tech markets need meaningful adaptation to work in B2B life sciences.

The Life Science Buyer Is Unlike Any Other B2B Buyer

Before discussing what makes ABM effective in life sciences, it is worth being precise about what makes life science buyers distinctive. Two characteristics stand out above all others.

Scientific skepticism. Life science professionals, whether Principal Scientists, Clinical Program Directors, or VPs of Research, are trained to evaluate evidence. Their entire professional formation is built around the careful assessment of data quality, methodology, and reproducibility. When they encounter marketing, they apply the same analytical lens. Promotional claims without supporting evidence are dismissed. Vendor messaging that is generic, technically shallow, or obviously optimized for persuasion rather than information is tuned out.

This means that the content-driven approach central to ABM of deploying technically substantive, expertise-demonstrating content to engage target personas is not just a nice-to-have in life sciences. It is the only category of marketing that this audience will meaningfully engage with. White papers grounded in real data, case studies documenting actual clinical or analytical outcomes, webinars led by genuine subject matter experts, and technical guides that help scientists solve real problems are examples of the type of content that drives positive engagement. ABM provides the framework for deploying that content to the right audience at the right time.

Purchasing conservatism. Life science purchase decisions are not made quickly, and they are not made lightly. The consequences of a poor vendor selection can be significant: a failed assay that delays a clinical trial, a manufacturing partner whose process fails to scale, a CRO whose regulatory expertise proves insufficient at the NDA stage. Vendors are evaluated not just on capability but on track record, regulatory rigor, quality systems, and the depth of the relationship they are willing to build.

This purchasing dynamic plays directly to ABM's structural strengths. ABM is designed for long sales cycles with multiple decision-makers. Its emphasis on nurturing every member of the buying committee over an extended period, which builds familiarity and credibility across the full group before a formal evaluation begins, aligns precisely with how life science buyers actually make decisions. The companies that are already known, trusted, and perceived as experts when a buying process formally begins have an advantage. ABM provides a systematic approach to build that familiarity and credibility.

Life Science Accounts Often Contain Multiple Independent Buying Groups

Beyond buyer psychology, life science organizations have a structural characteristic that makes ABM particularly valuable: within a single account, there are often multiple distinct buying groups, each tied to a different program, trial, or research initiative, each with its own decision-makers, timeline, and purchasing needs.

A mid-size biopharmaceutical company running four clinical programs might have a buying group forming around a biomarker assays needed for a Phase 1-stage program, a separate group evaluating outsourced manufacturing for a Phase 3 asset, and a third group assessing clinical data management solutions for a Phase 2 trial. These three groups share an employer but not a budget, not a decision-making process, and not a set of needs.

In a traditional broad marketing approach, the commercial team would often have a limited picture of who the relevant stakeholders were for the most in-market programs. ABM, particularly contact-level ABM using platforms like Influ2 or Propensity, enables the ability to identify which individuals at the account are engaging and what content they are engaging with. this helps map stakeholders to specific programs and needs, which can better uncover opportunities and enable sales outreach to be more targeted and effective - both in who is reached out to, and in what messaging is used in that outreach.

This reality of multiple programs also means that a single target account in life sciences can yield multiple distinct commercial opportunities over time. An ABM program that successfully engages the first buying group, delivers a strong outcome, and builds a genuine relationship within that account is positioned to identify and engage the next buying group as a new program advances. In life sciences, account depth (the degree to which a vendor is embedded across multiple programs and buying groups within a strategic account) is a major driver of long-term revenue, and ABM can help build this.

Why Standard ABM Tools Miss the Mark in Life Sciences

If ABM is so well-suited to life sciences, why do so many life science companies find that off-the-shelf ABM platforms underdeliver?

The answer lies primarily in intent data. Widely-used tools for determining “intent” and finding in-market accounts like 6Sense and Bombora build their intent models around web search behavior and content consumption patterns detected through publisher networks. These signals are effective at identifying when a company is actively researching a specific category of B2B software: an unusual volume of employees visiting competitor websites, searching industry-specific keywords, or reading relevant analyst reports.

In life sciences, this kind of keyword-based, web-behavior intent data captures only a fraction of the signals that actually predict purchasing intent. The most valuable in-market signals in this sector frequently are explicit, publicly available events that standard intent data platforms are not designed to monitor:

A new funding round: a Series B, C, or D, an IPO, or a significant partnership or licensing deal, frequently triggers program advancement and the engagement of new or expanded vendor relationships. A biotech that just closed a $150M Series C to advance its lead oncology asset into Phase 2 is a highly actionable target. Standard ABM platforms will not surface this signal unless the company coincidentally happens to be searching relevant keywords at the same time.

A clinical trial filing signals that a specific program is advancing and that a buying group is likely forming around the services and capabilities needed to execute that trial. These filings are public and structured, but they are not indexed by standard ABM intent platforms.

A regulatory milestone like a Fast Track designation, a Breakthrough Therapy designation, an NDA filing compresses timelines and creates urgent purchasing needs around the capabilities required to reach or respond to that milestone. These events are highly predictable in their commercial implications, but invisible to standard intent platforms.

Similarly, grant awards in the academic and government research sector, including NIH R01s, BARDA contracts, and DoD funding, are among the clearest intent signals for vendors serving this segment.

Life science-specific data platforms that aggregate clinical trial registries, funding databases, regulatory filings, pipeline intelligence, and grant award data provide a categorically different quality of intent signal for this sector. These should generally be primary signals. Then, overlaying keyword-based web intent data on top of these signals can often supplement and enhance the data to creates a more nuanced picture of in-market accounts.

The Takeaway

ABM works in life sciences not because it is a clever tactic, but because the structure of the approach maps almost perfectly onto the realities of the market: long sales cycles, conservative buyers, technically demanding audiences, complex multi-stakeholder purchasing processes, and accounts that contain multiple distinct commercial opportunities simultaneously.

What requires adaptation is not the foundational framework of ABM, but the specific tools and data sources used to execute it. Generic intent signals, tech-focused platforms, and SaaS-derived playbooks need to be replaced or supplemented with life-science-specific data intelligence, modality and pipeline-aware targeting, and content strategies calibrated for scientifically trained audiences.

Organizations that make the adaptation to approach ABM as a life-science-native capability rather than a technology-market import put their commercial resources behind an approach built for how this market actually buys.